(Total Views: 459)
Posted On: 06/03/2019 12:15:40 PM
Post# of 74

$SGEN News Article - Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer https://marketwirenews.com/news-releases/aste...88380.html


My Twitter: WhyteStocks